FIBROSIS is one of the main characteristic of chronic kidney disease (CKD) with progressive loss of renal function. A broad variety of diseases, such as glomerulonephritis, diabetes, or hypertension, cause CKD. Damage to glomeruli, tubules, or renal vessels can trigger CKD progression toward diffuse fibrosis (23, 24) . One of the most relevant events in CKD progression is inflammation. Inflammation is a physiological response to endogenous or exogenous insults characterized by activation of intrinsic renal cells to synthesize bioactive mediators, thus leading to tissue repair. However, an abnormal, persistent inflammatory response may lead to increased synthesis and deposition of extracellular matrix proteins with subsequent fibrosis (22) .
In recent years, the cytokine TNF-like weak inducer of apoptosis (TWEAK) has been identified as a new mediator of kidney inflammation (8) . TWEAK is a member of the TNF superfamily that activates the membrane FGF-inducible 14 (Fn14) receptor (59) . TWEAK is a multifunctional cytokine involved in physiological and pathological functions: cell proliferation, inflammation, angiogenesis, differentiation, and migration (2) . In the kidney, tubular and glomerular cells are the main sources of TWEAK and also express the Fn14 receptor. TWEAK elicits biological responses in these cells in a cell type-and microenvironment-dependent manner (10, 40) . Although recent studies have suggested that TWEAK is a relevant mediator in renal inflammation, there is scarce information about its role in the progression of renal fibrosis. Recent studies have suggested that TWEAK can contribute to the development of chronic fibrosis at several organs (6, 15, 31, 35, 52) and skeletal muscle atrophy (29) ; however, further studies are required to know the exact mechanism involved.
Transforming growth factor (TGF)-␤ is a key molecule in renal fibrosis. There are three isoforms belonging to the TGF-␤ superfamily: TGF-␤ 1 , TGF-␤ 2 , and TGF-␤ 3 . The most abundant is TGF-␤ 1 (46) . TGF-␤ 1 overexpression causes renal fibrosis (18) . TGF-␤ 1 is regulated by molecules such as ROS, collagens, heat shock protein 70, angiotensin, or glucose (12, 13, 16, 33, 34, 39, 53, 60) . In turn, TGF-␤ 1 directly stimulates the synthesis of extracellular matrix proteins such as fibronectin (16) , collagen (17) , or connective tissue growth factor (58) .
Previous studies have shown a relationship between TGF-␤ and the nitric oxide (NO) vasodilatory pathway (56, 61) . In general, NO inhibits the increased extracellular matrix protein synthesis induced by TGF-␤, and a report (45) has supported the ability of this system to inhibit the synthesis of TGF-␤ 1 . In this pathway, PKG is a widely expressed serine/threonine protein kinase. cGMP binds to PKG, resulting in the phosphorylation and activation of PKG and in the phosphorylation of target intracellular proteins such as vasodilator-stimulated phosphoprotein (VASP) (20) . Mammalian cells express PKG-I and PKG-II, which are products of two distinct genes (32) . PKG-I controls many cell functions, including the relaxation of contractile cells induced by different mechanisms (49, 51) as well as cell growth (7), differentiation (21) , apoptosis (47) , and gene regulation (37) .
Activation of PKG inhibits the synthesis of TGF-␤ (56). Moreover, a proinflammatory environment may decrease PKG levels, a fact that could be linked to increased TGF-␤ synthesis (1) . Although the best known mechanism of PKG activation is the increased synthesis of intracellular cGMP, a report (4) has provided evidence showing that protein content may also be regulated by other mechanisms. Particularly, recent results from our group have pointed to H-Ras downregulation as a mechanism involved in the regulation of PKG content (5) .
Considering these facts, the present study explored the possibility that TWEAK may modulate TGF-␤ 1 synthesis through the regulation of PKG as a molecular key in this pathway.
MATERIALS AND METHODS
Reagents. FBS, lipofectamine, antibiotics, RNAlater solution, the High Capacity cDNA Reverse Transcription Kit, and TaqMan gene expression assays were from Life Technologies (Carlsbad, CA). Culture media (RPMI 1640) were from Lonza (Basel, Switzerland). TGF-␤ 1 and fibronectin antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA) and Abcam (Cambridge, UK), and collagen type I was from Abcam. PKG-I and phospho-ERK1/2 antibodies were from Cell Signaling (Danvers, MA). Anti-phospho-VASP antibody and soluble recombinant human TWEAK were from Alexis (Läufelf-ingen, Switzerland). Anti-Ras antibody was from BD Bioscience (Oxford, UK). Anti-rabbit antibody was from Dako (Barcelona, Spain). The Dual-Luciferase Reporter Assay System and ELISA kit were from Promega (Madison, WI). The ERK1/2 inhibitor PD-98059 was from Selleck Chemicals (Houston, TX). Chemiluminescence reagent was from Thermo Scientific (Basingstoke, UK). The MassonGoldner kit was from Merck (Darmstacit, Germany). The FastStart DNA Master SYBR Green I Kit was from Roche (Mannhein, Germany). Other reagents were from Sigma Chemical (St. Louis, MO).
Animal model. The study was conducted and approved in accordance with the Animal Care and Use Committee of the University of Alcalá (2011/002). H-Ras-deficient (H-Ras Ϫ/Ϫ ) mice (8) at 8 -12 wk old received a single intraperitoneal injection of 0.7 g/mouse of TWEAK or saline (n ϭ 7 mice/group) 24 h before euthanization. Another group of animals received three doses of TWEAK for 10 days (0.7 g/mouse of TWEAK or saline, n ϭ 6 mice/group of H-Ras and H-Ras Ϫ/Ϫ mice) and were then euthanized. The kidneys were perfused in situ with cold saline before removal. Part of the kidney cortex was conserved in RNAlater solution for mRNA and protein experiments, and another part was fixed and paraffin embedded for histological experiments. Cell culture and treatments. Human mesangial cells (HMCs) were obtained as previously described (16) . HMCs from passages 3-8 were used. Cells were maintained in culture medium (RPMI 1640) supplemented with 10% FBS, 100 U/ml penicillin, and 100 g/ml streptomycin. Cells were serum deprived for 24 h and then treated with TWEAK (100 ng/ml) for 24 h.
Western blot analysis. Cells were washed with cold PBS, lysed [50 mM Trizma (pH 8.0), 150 mM NaCl, 0.1% Triton X-100, 10 mM EDTA, 0.25% sodium deoxycholate, and protease inhibitors] and then sonicated. Protein samples were run on 8 -12% SDS-PAGE gels and then transferred to polyvinylidene difluoride membranes, which were blocked with 5% nonfat dry milk in 50 mM Trizma (pH 7.6), 150 mM NaCl, and 0.1% Tween 20. Samples were then incubated overnight at 4°C with the corresponding primary antibodies and then for 1 h at room temperature with secondary antibodies. Immunoblots were detected by chemiluminescence. Densitometry analyses were done using ImageJ software (National Institutes of Health).
ELISA. After treatment, cell culture medium was removed and incubated with 1 M HCl to activate latent TGF-␤ 1. Supernatants were neutralized with 1 M NaOH. The TGF-␤1 content in the supernatant was then analyzed using a commercial TGF-␤1 ELISA kit according to the manufacturer's instructions. Samples were normalized to the total protein content, and the results were expressed as picograms of TGF-␤ 1 per microgram of protein.
Quantitative RT-PCR. Total RNA was extracted and quantified, and 2 g of total RNA were retrotranscribed to cDNA with the High Capacity cDNA Reverse Transcription Kit; 250 ng of this cDNA were used as a template for PCR amplification with the LC FastStart DNA Master SYBR Green I Kit following the manufacture's instructions. The following primers were used: mouse PKG-I, 5=-GTTTGGAGAGAAAGCGT-TGC-3= (forward) and 5=-TTCTGCGGCAATAACATTTG-3= (reverse); human PKG-I, 5=-GGACGAACTGATCCAGAAGC-3= (forward) and 5=-AGATCCTGGATGTCGAAGG-3= (reverse); mouse TGF-␤ 1, 5=-TTGCTTCAGCTCCACAGAGA-3= (forward) and 5=-TGGTTG-TAGAGGGCAAGGAC-3= (reverse); mouse collagen type I, 5=-TCCTGGCAACAAAGGAGACA-3= (forward) and 5=-GGGCTCCTG-GTTTTCCTTCT-3= (reverse); mouse fibronectin, 5=-AGACCATACC-TGCCGAATGTAG-3= (forward) and 5=-GAGAGCTTCCTGTCCT-GTAGAG-3= (reverse); mouse GAPDH, 5=-CCACCCAGAAGACT-GTGGAT-3= (forward) and 5=-CAGATTGGGGGTAGGAACAC-3= (reverse); and human GAPDH, 5=-TCCACTGGCGTCTTCACC-3= (forward) and 5=-GGCAGAGATGATGACCCTTTT-3= (reverse). Similar amount of cDNA were analyzed for TGF-␤ 1 (Hs00171257 m1) and GAPDH (4326317E) as endogenous controls using TaqMan gene expression assays. The normalized gene expression method (2 Ϫ⌬⌬CT , where CT is threshold cycle) for the relative quantification of gene expression was used.
Transient transfection and luciferase assays. Cells were transfected using lipofectamine reagent with 0.1 g of human PKG reporter (kindly provided by Dr. Lincoln and Dr. Sellak, University of South Alabama) and 0.01 g of Renilla luciferase reporter as an internal control. Afterward, cells were serum deprived for 24 h, stimulated, and lysed, and their luciferase activity was measured with the DualLuciferase Reporter Assay System according to the manufacturer's instructions.
Dominant negative Ras transfection. To delete Ras activity, HMCs were transfected with 1 g of a plasmid containing dominant negative Ras (ND-Ras; kindly provided by Dr. Chiloeches, University of Alcalá, Alcalá, Spain) with lipofectamine reagent. Cells were then serum deprived for 24 h, treated, and lysed for Western blot analysis.
Pulldown assay. To analyze the amount of active Ras, we examined the capacity of Ras-GTP to bind to Ras-binding domain of Raf-1 (RBC). HMCs were serum deprived for 24 h before the addition of TWEAK and then lysed in 300 l of Ras extraction buffer [20 mM Tris (pH 7.4), 1 mM EDTA, 10% (vol/vol) glycerol, 100 mM KCl, 5 mM MgCl 2, 1 mM DTT, 1% Triton X-100, 0.5% (vol/vol) ␤-mercaptoethanol, 5 mM NaF, 0.2 mM NaVO4, and protease inhibitors]. Lysates were centrifuged (13,000 rpm, 5 min, 4°C). Supernatants (30 l) were tested by Western blot analysis. The remainder (270 l) was incubated with sepharose beads bound to glutathione-S-transferase (GST) fusion protein containing RBD (GST-Raf1-RBD) for 2 h. Beads were washed four times with wash buffer and boiled in SDS loading buffer. Eluted proteins were resolved by 12% SDS-PAGE, and the amount of Ras in the bound fraction was analyzed by Western blot analysis using a specific Ras antibody to detect Raf-1-bound Ras (Ras-GTP).
Histological experiments. Kidneys were fixed, dehydrated, and embedded in paraffin. Sections of 3 m thick were cut, mounted on (Fig. 1A) and time-course (Fig. 1B) experiments in serum-deprived HMCs treated with TWEAK by Western blot analysis. We observed an increase in protein content at progressively higher doses and times, which was detected at TWEAK concentrations of 20 ng/ml and reached a maximum at 100 ng/ml (this concentration was used in the following experiments to better discriminate the differences). We then evaluated TGF-␤ 1 protein content in incubation media as well as TGF-␤ 1 mRNA content in serum-deprived HMCs treated with TWEAK for 24 h. We observed an upregulation of TGF-␤ 1 protein release to supernatants, as assessed by ELISA (Fig. 1C) . Furthermore, TWEAK also upregulated TGF-␤ 1 mRNA levels, suggesting regulation at the transcriptional level (Fig. 1D) .
To explore the bioactivity of the increased TGF-␤ 1 induced by TWEAK, we examined whether TWEAK-stimulated fibronectin expression was prevented by anti-TGF-␤ 1 -neutralizing antibodies. We found that TWEAK induced fibronectin synthesis, which was diminished with anti-TGF-␤ 1 -neutralizing antibody (Fig. 1E) . These results showed that in HMCs, TWEAK upregulated TGF-␤ 1 and TGF-␤ 1 -dependent fibronectin expression.
TWEAK induces TGF-␤ 1 synthesis through Ras-ERK1/2 pathway activation in HMCs. Ras proteins are small G proteins that act as a molecular switch between inactive GDP-bound and active GTP-bound cycles (25) . Ras is involved in cell proliferation through activation of its effector, Raf, which recruits the MAPK cascade (28) and ERK1/2 (50).
To evaluate in our system whether the Ras pathway is involved in TWEAK signaling, we examined the activation of Ras protein. We used RBD, which specifically binds the active GTP-bound form of Ras (38) . In serum-deprived HMCs, TWEAK promoted association of the GST-RBD fusion protein to Ras above basal levels, indicating activation of Ras ( Fig.  2A) . Under the same experimental conditions, immunoblots showed that TWEAK induced ERK1/2 phosphorylation (Fig. 2B) . The contribution of Ras to TWEAK-induced ERK1/2 phosphorylation was assessed in HMCs transfected with ND-Ras. This mutant was successfully transfected into HMCs, as an increase of total Ras in ND-Ras-transfected cells was observed. In ND-Ras-transfected cells, TWEAK failed to phosphorylate ERK1/2 (Fig. 2C) . These results indicate that TWEAK leads to ERK1/2 phosphorylation through Ras activation.
To establish whether there is a relationship between TGF-␤ 1 induction and Ras-ERK1/2 activation by TWEAK, we analyzed TGF-␤ 1 protein content in serum-deprived HMCs pretreated for 15 min with the well-known MEK inhibitor PD-98059 at 50 M or HMCs transfected with ND-Ras and then treated with TWEAK. Under these conditions, TWEAK failed to induce TGF-␤ 1 protein expression (Fig. 3, A and B) . We also observed significant ERK1/2 phosphorylation induced by TWEAK, which was inhibited by PD-98059 (Fig. 3C) . These results clearly show that TWEAK induces TGF-␤ 1 protein synthesis through Ras-ERK1/2 pathway activation.
TWEAK induces TGF-␤ 1 synthesis through PKG-I inhibition in HMCs.
Previous studies have shown a relationship between TGF-␤ 1 and PKG-I (53, 54). To determine whether TWEAKinduced TGF-␤ 1 expression in HMCs was PKG-I dependent, we analyzed whether TWEAK regulated PKG-I levels in serum-deprived HMCs.
TWEAK decreased cell PKG-I content, as assessed by Western blot analysis (Fig. 4A) , and steady-state PKG-I mRNA levels, as assessed by real time RT-PCR (Fig. 4B) . PKG-I promoter activity evaluated by a luciferase assay (Fig. 4C) , and PKG-I activity was assessed as phosphorylation at Ser 239 of VASP (Fig. 4D) (48) . To prove that PKG-I downregulation is critical in TWEAKdependent TGF-␤ 1 stimulation, we added the cGMP analog 8-bromo-cGMP (8-BrcGMP; 1.0 mM), a PKG agonist, 30 min before TWEAK. 8-BrcGMP increased the levels of Ser 239 -phosphorylated VASP, both under basal conditions and after stimulation with TWEAK (Fig. 5A) . Furthermore, 8-BrcGMP prevented TWEAK-induced TGF-␤ 1 upregulation (Fig. 5B) .
Changes in PKG-I depend on modulation of the Ras/ERK1/2 pathway. To determine whether PKG-I downregulation is dependent on Ras-ERK1/2 pathway activation, we designed two strategies. First, HMCs were transfected with ND-Ras and then treated with TWEAK (100 ng/ml) for 24 h. Ras pathway blockade by ND-Ras increased PKG-I protein content and mRNA levels in the presence of TWEAK (Fig. 6, A and B, respectively) . In addition, ND-Ras prevented downregulation of PKG-I activity, as assessed by VASP phosphorylation (Fig. 6C) . Second, we preincubated serum-deprived HMCs for 15 min with the ERK1/2 phosphorylation inhibitor PD-98059 (50 M) before adding TWEAK (100 ng/ml) for 24 h. PD-98059 decreased TWEAK-induced ERK1/2 phosphorylation (Fig. 3C ) and prevented TWEAKinduced PKG-I mRNA downregulation (Fig. 6D) .
Taken together, these results suggest, for the first time, a new relationship between Ras and PGK-I in HMCs treated with TWEAK.
In vivo exogenous TWEAK decreases PKG-I and increases TGF-␤ 1 through an H-Ras-dependent pathway. The relationship between TWEAK, Ras, and TGF-␤ 1 in vivo was explored in the renal cortex of wild-type and H-Ras Ϫ/Ϫ mice. After 24 h of the systemic injection of TWEAK in H-Ras ϩ/ϩ mice, increased kidney cortex TGF-␤ 1 mRNA (Fig. 7A ) and protein content (Fig.  7B) as well as decreased PKG-I protein content (Fig. 7D ) and VASP phosphorylation (Fig. 7E) differences in PKG-I mRNA levels were not statistically significant (Fig. 7C) . No changes in these parameters were observed in H-Ras Ϫ/Ϫ mice treated with TWEAK (Fig. 7) . H-Ras Ϫ/Ϫ mice exhibited higher levels of PKG-I under basal conditions (Fig. 7,  C-E ). An increase of ERK1/2 phosphorylation in H-Ras ϩ/ϩ mice treated with TWEAK but not in H-Ras Ϫ/Ϫ mice (Fig. 7F ) was also observed. These results demonstrate that TWEAK regulation of PKG-I and TGF-␤ 1 requires H-Ras.
To explore the possible induction of fibrotic proteins by TWEAK in our in vivo conditions, we analyzed mRNA levels of collagen type I and performed histological experiments with Sirius red staining and Masson's trichrome staining. No significant kidney fibrosis was observed after 24 h of TWEAK treatment (data not shown).
Thus, to probe that TWEAK is really able to induce renal fibrosis in vivo, we analyzed mRNA levels and protein expression of collagen type I and fibronectin (two of the more relevant protein involved in fibrosis) in the cortex kidney of mice treated with TWEAK for 10 days with three doses. Our results clearly showed a significant increment of both protein expression and mRNA levels in H-Ras ϩ/ϩ mice treated with TWEAK but not in H-Ras Ϫ/Ϫ mice (Fig. 8, A-D) . Histological experiments confirmed these findings. Kidneys from H-Ras ϩ/ϩ mice treated with TWEAK showed an increased extracellular matrix deposition at the glomerular and interstitial levels that was not observed in H-Ras Ϫ/Ϫ mice (Fig. 8E) .
DISCUSSION
TWEAK is a well-known inflammatory cytokine that activates signaling pathways and gene expression by engaging several pathways, such as activation of TGF-␤-activated kinase 1 (19) and canonical and noncanonical NF-B pathways (3, (42) (43) (44) . However, the role of TWEAK in renal fibrosis is still not clear.
In the present study, we show that TWEAK is a potent inducer of TGF-␤ 1 mRNA and protein expression as well as TGF-␤ 1 -dependent fibronectin upregulation in HMCs. However, the known intracellular pathways activated by TWEAK differ from the pathways known to regulate TGF-␤ 1 expression. Therefore, we explored potential intracellular signaling pathways linking TWEAK to TGF-␤ 1 expression by focusing on pathways known to promote fibrosis, such as the Ras pathway (27) . Some reports have previously described that TGF-␤ 1 can activate Ras signaling and its effectors, such as ERK1/2 (26, 36, 41), but there is no information on the role of Ras in the regulation of TGF-␤ 1 expression.
In this work, we show that TWEAK can activate Ras/ ERK1/2 signaling in HMCs. The critical role for Ras in TGF-␤ 1 regulation is supported by the finding that TWEAKinduced TGF-␤ 1 expression was prevented by inhibition of the Ras pathway with ND-Ras or with the selective ERK1/2 inhibitor PD-98059.
To advance the understanding of the mechanisms involved in TWEAK-induced TGF-␤ 1 upregulation, we analyzed an important protein involved in fibrosis, PKG-I. The upstream position of PKG-I in the regulation of TGF-␤ 1 expression induced by trombospondin-1 has been previously described in vascular and renal cells (53) (54) (55) . In our work, we demonstrated, for the first time, that in kidney cells TWEAK downregulated PKG-I mRNA, protein expression, and activity. Our results also support the upstream role of PKG-I activation in the regulation of TGF-␤ 1 expression, since the PKG agonist 8-BrcGMP prevented TWEAK-induced TGF-␤ 1 upregulation. These data are in accordance with previous reports (53, 54) in which changes in PKG protein expression and activity can modulate TGF-␤ 1 activity and matrix protein expression by several stimuli. Moreover, it has been also demonstrated that enhancement of renal cGMP levels is an effective antifobrotic approach (57), although a direct implication for PKG has not been demonstrated yet.
Our group has previously shown that PKG-I protein and activity are upregulated in H-Ras-deficient mice, illustrating the relationship between Ras and PKG-I (5). With these precedents, we studied whether, in HMCs, the Ras pathway mediates TWEAK-induced PKG-I downregulation. Inhibition of the Ras pathway with ND-Ras or with the selective ERK1/2 inhibitor PD-98059 prevented PKG-I downregulation by TWEAK. The mechanism linking Ras activation to suppression of PKG-I expression is still not well understood. Downregulation of PKG-I and promotion of fibrosis by stimuli such as NO (10) (14) and that H-Ras and Erk signaling were required for TGF-␤ 1 -dependent fibroblast proliferation (26). The role of PKG has not been analyzed in this context.
Our data strongly support a relevant role for H-Ras protein as a key mediator in fibrotic kidney injury induced by TWEAK and the key role for PKG in this pathway. It has been demonstrated that chronic TWEAK overexpression by itself promotes renal fibrosis in mice without underlying kidney injury after 20 days, and in a renal model of fibrosis in mice TWEAK deficiency decreased fibrosis (52) . In our work, the in vivo results are in accordance with these findings, as a single TWEAK injection in mice without renal injury was enough to initiate the upregulation of fibrotic proteins such as TGF-␤ 1 , the most important switch in fibrosis development. We could not observe significant kidney fibrosis at 24 h after TWEAK treatment, as it would be expected more days and repeated injections to observe an increase in fibrosis. However, the significant increase of TGF-␤ 1 in our in vivo model in H-Ras ϩ/ϩ mice treated with TWEAK, at a very early stage, suggests that fibrosis is switch on. These results are very relevant, since this is the first time that it has been shown that exogenous TWEAK induces very early effects on TGF-␤ 1 expression. This can be a relevant result to demonstrate that at the beginning of kidney injury, where inflammatory cytokines start to increase, the fibrotic process is initiated. Moreover, we showed that TWEAK can really induce fibrosis, because we observed a relevant increase of fibrotic proteins (such as collagen type I and fibronectin) as well as histological changes in the kidneys of mice treated with TWEAK for 10 days but not in H-Ras-deficient mice. This TWEAK effect could be specific, since other cytokines from the same family, such as TNF-␣, had no significant effect in renal fibrosis after unilateral ureteral obstruction (30) .
We have also observed that, under our in vivo conditions, TWEAK induced Fn14 overexpression (data not shown), as previously reported (42) . Upregulation of Fn14 expression can be a key effect to sensitize the kidneys to TWEAK actions (59) and trigger signaling that can induce fibrosis.
Therefore, these results suggest a novel pathway regulating TGF-␤ 1 activity: TWEAK activation of Ras would facilitate the fibrotic response through PKG-I downregulation and subsequent TGF-␤ 1 upregulation. The present results are of interest to better understand the molecular mechanisms of fibrosis progression in kidney injury. We have identified a novel role for PKG-I in the pathway regulating TWEAK-induced TGF-␤ 1 production that may be of interest for developing new therapeutic strategies in kidney fibrosis. 
